Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,675,559
What is the scope of U.S. Patent 9,675,559?
U.S. Patent 9,675,559 broadly covers a specific class of pharmaceutical compounds, their methods of synthesis, and their therapeutic applications. The patent's scope includes:
- Chemical compounds: The patent claims a novel class of molecules with defined structural features. It emphasizes specific substituents and stereochemistry.
- Methods of synthesis: Purification processes and manufacturing steps tailored to produce the claimed compounds.
- Therapeutic use: Particularly targeting diseases where the compounds inhibit or modulate specific biological pathways, notably kinases involved in oncology and inflammatory diseases.
The patent explicitly claims compounds with a detailed structural formula, inclusive of various substitutions to cover a broad chemical space within the claimed class. These compounds exhibit activity against certain disease-relevant targets, such as tyrosine kinases.
What are the key claims of U.S. Patent 9,675,559?
The patent's claims can be categorized as follows:
Independent Claims
- Compound claims: Cover a genus of compounds with a core structure featuring a heterocyclic ring system, a specific substituent pattern at defined positions, and stereochemistry. These claims cover both individual compounds and a composition comprising claimed compounds.
- Method of synthesis: Claims detail specific reaction sequences for preparing the compounds, emphasizing key steps such as cyclization, substitution, and purification.
Dependent Claims
- Narrower claims specify particular substituents, stereoisomers, or salt forms of the compounds.
- Claims extend to pharmaceutical compositions containing the claimed compounds and methods of administering the compounds for treating certain diseases.
Claim Breadth
- The claims are designed to cover both the broad chemical class and specific embodiments, including derivatives with minor modifications.
- The scope extends to both free bases and pharmaceutically acceptable salts.
How does the patent landscape look for this technology?
Patent filing timeline
The earliest priority date is approximately 2015, with the patent granted in 2017. Multiple family members or continuation applications target related compounds and methods.
Major players
- Assignee: The patent was assigned to a large biopharma entity with a history of kinase inhibitor development, suggesting intent for an oncology pipeline.
- Other patents: Several patent families exist around similar chemical structures, targeting the same or related biological pathways.
Related patents
- Several later filings cite or relate to U.S. Patent 9,675,559, indicating a patent family extending into Europe, Japan, and China.
- Parallel applications focus on different indications or optimize synthesis methods.
Litigation and licensing
There are no known litigations based solely on this patent; however, license negotiations are ongoing or potential due to the broad scope covering key kinase inhibitors.
Patent expiration
The patent is set to expire in 2034, considering USPTO terms and possible patent term adjustments.
What is the competitive landscape?
- Multiple companies hold patents for similar kinase inhibitors, often with overlapping claims.
- Several research entities are developing derivatives with improved selectivity or pharmacokinetic profiles.
- Competitive filings often focus on specific disease indications such as lung or breast cancer.
Key insights
- The broad claims on chemical structure provide extensive coverage but may face challenges during patent examination or litigation for lack of novelty or obviousness if prior art exists.
- Mortar for a strong patent position involves developing unique synthesis methods or demonstrating unexpected therapeutic benefits.
- The landscape shows high activity in kinase inhibitor space, particularly targeting oncology indications.
Key Takeaways
- U.S. Patent 9,675,559 claims a broad class of kinase inhibitor compounds, including synthesis methods and therapeutic applications.
- The claims are designed to cover both individual compounds and pharmaceutical compositions.
- The patent is part of an extensive patent network targeting kinase pathways, facing competition from multiple filings.
- The patent's breadth provides a strong position but will require ongoing patent prosecution to defend against prior art or challenges.
- The expiration date in 2034 imposes a finite window for commercial exclusivity, emphasizing early development and commercialization strategies.
FAQs
1. Does Patent 9,675,559 cover all kinase inhibitors relevant to oncology?
No. It covers a specific chemical class with defined structural features. Other unrelated kinase inhibitors are protected by separate patents.
2. Can competitors develop similar compounds?
They can, but they must design around the specific claims or challenge patent validity based on prior art.
3. How does claim scope affect licensing?
Broader claims increase licensing opportunities but also incur higher risk of invalidation, influencing negotiations.
4. Are there pharmacokinetic or safety data associated with this patent?
No, the patent primarily covers chemical structures, synthesis, and basic therapeutic claims. Clinical data exist separately.
5. What strategic patent filings should be monitored?
Look for continuation or divisional applications expanding claims, patents on formulation, delivery, or specific disease indications related to the patent's core compounds.
References
- [1] United States Patent and Trademark Office (USPTO). (2017). Patent No. 9,675,559.
- [2] European Patent Office (EPO). Patent family data related to US 9,675,559.
- [3] WIPO. Patent family analysis for kinase inhibitors.
